Berend Jan van der Wilk

Berend Jan van der Wilk is a researcher in the Department of Surgery at Erasmus MC, focusing on clinical and translational research in esophageal cancer. His work is deeply embedded in large-scale, multi-center clinical trials, particularly the SANO trial, which investigates whether active surveillance can be a safe alternative to surgery following neoadjuvant chemoradiotherapy.

His research interests lie at the intersection of surgical oncology, cancer therapeutics, and patient outcomes. Key areas include esophageal cancer management, neoadjuvant chemoradiotherapy, detection of minimal residual disease, and prognostic modeling. He leverages large databases like SEER and designs prospective multicenter trials to improve decision-making in oncology.

The recent publications highlight a strong trend toward re-evaluating standard surgical paradigms in favor of organ-preserving strategies. His work spans clinical trial methodology, survival analysis, and diagnostic accuracy studies, reflecting a multidisciplinary approach to advancing gastrointestinal oncology.

Scientific Awards:

Berend Jan van der Wilk has been actively involved in securing and executing major clinical research grants, particularly those funding the SANO and preSINO trials. These projects involve collaboration across numerous institutions and are supported by significant academic and clinical consortia. While specific grant names are not listed, the scale and impact of his publications suggest substantial research funding. He contributes to mentoring within collaborative research teams and plays a key role in data analysis and dissemination.

He is part of a robust research network centered around the SANO study group and collaborates extensively with leading experts in surgical oncology, including J.J.B. van Lanschot and B.P.L. Wijnhoven. This team operates at the forefront of innovation in esophageal cancer treatment, aiming to reduce unnecessary surgeries and improve quality of life for patients.